Trials / Completed
CompletedNCT03070353
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Ramathibodi Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI
Detailed description
A pilot study of Dextran-40 infusion in decompensated cirrhotic patients complicating with AKI. Dextran-40® was administered at 1 g/kg/day for two days. AKI reversal was defined when serum creatinine was \< 1.5 mg/dL. Albumin infusion was given if AKI reversal did not occur.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dextran 40 | Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days. |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-06-30
- Completion
- 2016-06-30
- First posted
- 2017-03-03
- Last updated
- 2017-03-03
Source: ClinicalTrials.gov record NCT03070353. Inclusion in this directory is not an endorsement.